Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Theralase's ACT doesn't need to be the cure for cancer
View:
Post by Eoganacht on Aug 04, 2023 2:16pm

Theralase's ACT doesn't need to be the cure for cancer

In a recent interview Roger said:

"The latest data that Theralase has put out - we had a 66 complete response rate at any point in time with 33 at 15 months. So dramatically higher than what's already been approved. So we think it bodes well for the future of the company. And it bodes well for value of the organization. Hopefully it bodes well for the shareholders and the stakeholders in the company as well."

Halfway through the phase 2, TLD1433 PDT has proven itself to be a better solution than the approved treatments for BCG-unresponsive NMIBC in terms of safety, efficacy and number of treatments.

15 month CR rates could be 10% or more higher by the end of the trial (43%+  CR).

I think there is no doubt whatsoever that TLD1433 PDT will benefit bladder cancer patients with very little down side and will be a valuable addition to the anti-cancer tools available.

And that should be all that is needed for BTD, AA and a dramatic rise in the stock price. Big pharmas should be tripping over each other to acquire Theralase.

I don't get why this is not happening. 

In the current trial TLD1433 PDT is being used on the most difficult to treat kind of NMIBC - high-grade BCG-unresponsive NMIBC with or without CIS. If it proves itself in this trial it could go head to head against BCG as a first line treatment and also be trialed for MIBC.

TLD1433 PDT could end up benefiting patients with all the varieties of bladder cancer - as a standalone treatment and/or an adjunct to other treatments.

And if it works with bladder cancer, there is a high probability it could be adapted for use against NSCLC, GBM, melanoma, colon, breast, pancreatis, esophageal etc. It doesn't have to totally cure any of these cancer types - just be of benefit to the patient - destroy tumours, or just shrink them and encourage the patient's own immune system to kick in.

And there is all the other research of Dr. McFarland waiting in the wings. All of the more potent ruthenium and osmium based photosensitizers that Theralase has rights to.

So why are we sitting at 27 cents with no money in the till?
Comment by BlueFranky on Aug 04, 2023 2:37pm
Good post eog.. count me In on the question you just raised The question I ask: Does Theralase have the goods already in hand, statistically speaking, to merit both BTD and AA simultaneously ... And are deals being sealed in the back rooms based on that possibility.. waiting in the wings for the fda's announcement accordingly? Because the facts are - we are superior to all comers, even at ...more  
Comment by N0taP00p on Aug 04, 2023 3:21pm
Very well said! It just doesn't make sense. Hopefully, just a matter of weeks. 
Comment by skys1 on Aug 04, 2023 4:12pm
Great post Eoganacht !!! The fact that several members of the Big Pharma community havn't already made a move on TLT is very surpriseing considering it is head & sholders it's competition. All will happen in due time.  
Comment by Legit62 on Aug 04, 2023 4:19pm
Skys1 i agree, i feel the BTD and AA takes the risk out IMO
Comment by skys1 on Aug 04, 2023 4:25pm
Agree Legit, After BTD & AA, a bidding war could ensue. 
Comment by ggrellette on Aug 04, 2023 5:03pm
Designations will definitely open many eyes and investors wallets. The biggest event those designations will do is bring big pharmas to the table. Yep JV partnerships. We all know when that will happen is when the volume suddenly increases substantially. 
Comment by Legit62 on Aug 04, 2023 4:16pm
Eog, i think its the exchange we are on and manipulation being played plus EXTREMELY low share volume, once we get BTD and AA i honestly believe we cross the barrier of keeping this down, hope soon after we get a JV or buyout, got to remember Roger has been at this for a long time and im sure he wants a big payout while he still has some good years in him, plus the notoriety that goes along with ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250